pathways and subnetworks that are critical for cell physiology and diseases. One such pathway is the PI3K/Akt/mTOR pathway, which is critical for regulating cell growth, proliferation, apoptosis, and glucose metabolism, and is frequently dysregulated in cancer. On the other hand, we also take a systems biology approach to analyzing signaling networks. For instance, in collaboration with Heng Zhu and Jiang Qian's laboratories at JHU, we developed a strategy based on functional protein microarrays and bioinformatics to experimentally identify substrates for 289 unique human kinases. We further constructed a high-resolution map of phosphorylation networks that connects 230 kinases to 2591 in vivo phosphorylation sites in 652 substrates, providing global insights into kinasemediated signaling pathways. In short, I could also say we work on whichever projects excite us most.
Tell us something about your work that is exciting for you right now I am very excited about testing our new 'activity architecture' hypothesis. The assembly/disassembly and enzymatic activities of protein nanomachines underlie all cellular functions, and dysregulated nanomachines are the ultimate culprits in cancer. Knowing when and where these nanomachines are active is, therefore, critical to understanding the molecular drivers for normal cellular functions as well as for tumorigenesis, yet current efforts to characterize the molecular constituents of the cellular machinery overlook this critical dimension. We seek to establish a new conceptual framework to specifically understand the cellular organization of molecular activities. We hypothesize that cellular biochemical activities are spatially organized into an 'activity architecture' via the specific organization of active molecules and their regulatory partners. This activity architecture, together with the structural and mechanical architecture of the cell, encodes all the information needed to drive cellular function. We further hypothesize that perturbations to this activity architecture, even by a few dysregulated driver molecules, could lead to detrimental effects on cellular functions, such as loss of control over cell growth, division, and death. We are developing a new generation of biosensor and imaging technologies to characterize the activity architecture of the cell and examine the dysregulated activity architecture in cancer cells. Figure 1A shows the allosteric ternary complex model [3] . No states are illustrated, only receptor complexes (R, DR, RA, and DRA). The parameters K 1 and K 2 represent the observed affinity constants (reciprocal of the concentration of ligand required for half-maximal occupancy) of the orthosteric (D) and allosteric (A) ligands, and a, the cooperativity constant. Thus, aK 1 represents the observed affinity constant of D when the receptor population is saturated with the allosteric ligand, and aK 2 , the observed affinity constant of A when the receptor population is saturated with the orthosteric ligand D.
In this population analysis, receptor activation is denoted by efficacy terms, (e D , e A , and e 0 ), which represent the fractions of the populations of the DR, RA, and unoccupied receptor (R) complexes in the active state, respectively. The parameter, b 1 , represents the scalar by which allosteric ligand A alters the efficacy of orthosteric ligand D (b 1 e D , fraction of the population of DRB complexes in the active state). The product of the allosteric effects on affinity (a) and efficacy (b 1 ) is denoted by the parameter, g 1 (g 1 = ab 1 ). This parameter is also equivalent to the ratio e A /e 0 and, hence, is determined by the allosteric ligand and constitutive activity.
In Figure 1B , the allosteric ternary complex model is illustrated by four populations of receptors representing the unoccupied (R) and the three types of occupied receptor complex (DR, RA, and DRA). In this example, each population contains 1000 receptors, and the active and inactive receptor states are denoted by yellow and blue colors, respectively. Given that each receptor complex (e.g., DR) represents a mixture of structures, there is no real receptor species that has an observed affinity of K 1 or an activity of e D . Rather, these parameters represent the weighted average values of the receptor population.
If we turn up the zoom lens ( Figure 1C ), the ligand-binding sites on each state can be seen to isomerize concertedly as the receptor transitions between states. The affinities of ligands for these states of the receptor are designated in the two-state
RA, ε A = 0.003 Figure 5A of my prior review [2] , which is shown here in a modified format ( Figure 1D Thus, the cooperativity of the more empirical allosteric ternary complex model ( Figure 1A ) does not arise because simultaneously bound allosteric and orthosteric ligands somehow change the structure of their respective sites by a scalar amount corresponding to the value of a, but rather, through a process of conformational induction. That is, the preferential binding of the positive allosteric ligand to the active state (i.e., K f /K e = 3.0) shifts the equilibrium between active and inactive states in the direction of the active state, causing an increase in the observed affinity of the agonist ( Figure 1D ). The vertical transitions show how the agonist, the allosteric ligand, and the combination of both ligands increase the isomerization constant (K q ) by factors of K act /K inact , K f /K e , and K act K f /K inact K e , respectively. This is the ultimate mechanism of cooperativity in the two-state model. How the fundamental state parameters give rise to the more superficial population parameters is described in Table 1 [5, 6] . These equations differ from those given by Zhang and Kavana [1] .
The two-state model can also be used to describe the behavior of a single receptor as it transitions through specific states [7] . The forward and reverse rate constants that define the receptor-state affinity constants can be used to calculate conditional probabilities for transitioning from a given state to adjacent states over a small time increment. The process is repeated iteratively to simulate the random behavior of the receptor in time (continuous Markov process). Figure 1E shows examples of single receptor behavior in the absence and presence of an allosteric modulator for the model shown in Figure 1D . It is impossible to use the population model ( Figure 1A ) for Markov analysis because there are no real receptor structures that correspond to the various receptor complexes in the model.
Presumably, the structure of the active state of the binding pocket of a GPCR when bound with a highly efficacious natural ligand is well defined, as are the more proximal sections of the helices that form it. However, there may be substantial movement of the cytosolic ends of the helices if there is no receptor-bound G protein to stabilize them. Similarly, the cytosolic ends of the helices may undergo movement in the inactive state even though the binding pocket may be stabilized. The two-state model is not based on the assumption of rigid receptor-state structures, but rather, on: (i) a capacity to induce a signal (active state) or not (inactive state); and (ii) specific binding-pocket structures with characteristic affinities. Of course, certain biased ligands can stabilize additional active states, and the latter can be included in a more complete multi-state model, as previously described [8] .
I have not expanded the allosteric ternary complex model ( Figure 1A ) into active and inactive receptor states as Hall [9] and others [1] have because the efficacy terms already account for these. Also, the use of observed affinities and cooperativity constants (/ and d [9] ) in these models implies additional undefined receptor states. The possible outcomes of these models greatly exceed those of receptor-state models and include behavior that is impossible if we assume that conformational induction is the engine that drives conformational change.
the allosteric modulator is manifest as an increase in both (i) receptor occupancy at low agonist concentrations; and (ii) the mean activation time of occupied receptors. The probability that a given type of ligand-receptor complex (e.g., DR s * + DR s ) is in the active state (DR* s ) is equivalent to the time spent in the active state divided by the total time that both R s and R s * are occupied by D. This probability is equivalent to the corresponding efficacy value given in (A) and (B) (i.e., e D ). For example, the expanded allosteric ternary-complex population model [9] includes in its suite of outcomes the case of two ligands that bind to their respective sites on a receptor and have no effect on receptor isomerization by themselves, but together cause substantial receptor activation (co-agonism). A problem with this mechanism has been described previously, as well as a more realistic explanation of co-agonism based on two receptor states [5] .
A seemingly harmless property of the allosteric ternary complex model is that it fits data for the case of an allosteric ligand that always modifies only the affinity of orthosteric ligands. While it is possible to describe a four-state model that can explain affinity modulation without a change in efficacy, it is nearly impossible to use the model to explain the affinity-only modulation of a diverse group of ligands acting at the same receptor [5] . In the case of a putative allosteric modulator that exhibits only negative affinity modulation (e.g., gallamine), perhaps its binding pocket is so close to the orthosteric site [10] that one of its vibrating chemical moieties intrudes into the orthosteric-binding pocket when unoccupied and impedes the association of orthosteric ligands, thereby reducing their observed affinity.
A more extreme form of this latter idea might explain why the muscarinic antagonist, atropine, causes a maximal 10 000-fold shift in the concentration-response curve of the ectopic agonist, AC-42 {4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine}, in a manner consistent with the prototypical limiting effect of allosteric antagonism [11] . Given the structure of AC-42, it might behave as a bivalent ligand that derives considerable affinity through the interaction of its 1-(1-oxobutyl) -2-methylbenzene moiety with an ectopic site on the muscarinic receptor, while its 4-n-butylpiperidine residue interacts with the orthosteric site to compete with atropine. Such an inhibitory mechanism is consistent with the behavior of the allosteric ternary complex model [12] . A consideration of the two-state model provides predictions regarding the efficacy of AC-42 that could be used to distinguish between allosteric and bivalent ligand mechanisms.
Expanded population models [1, 9] seem to be favored because of their ability to describe a variety of experimental observations and to account for an unlimited number of receptor states. My view is more in line with that of Lander [13] , who suggests that the value of models is not so much in their ability to describe data so much as how they help us to understand biology. The demonstration of a lack of consistency of functional data with a simple two-state model is useful because it helps us understand how drugs interact with receptors. It gives us a reason to consider additional defined states or perhaps to consider fundamentally different models.
